1 / 7

Switch to NNRTI

The DRIVE-SHIFT study evaluates the efficacy and safety of switching to DOR/3TC/TDF compared to continuation of baseline cART. Results demonstrate non-inferior efficacy, no emergence of resistance, and a favorable safety profile. Higher incidence of adverse events observed in participants who switched to DOR/3TC/TDF compared to continuation of baseline regimen. Superior lipid profile for LDL-cholesterol and non-HDL cholesterol with DOR/3TC/TDF.

eulerd
Télécharger la présentation

Switch to NNRTI

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. Switch to NNRTI • Switch to DOR/3TC/TDF • DRIVE-SHIFTStudy

  2. DRIVE-SHIFT Study: Switch to DOR/3TC/TDF • Design Randomisation * 2:1 Open-label W24 W48 HIV+ ≥ 18 years HIV RNA < 40 c/mL ≥ 6 months On 2 NRTI + PI/b or EVG/c or NNRTI No prior virologic failure No major resistance mutation to DOR, 3TC or TDF eGFR ≥ 50 mL/min N = 447 N = 223 • Endpoints • Primary: % of patients maintaining HIV RNA < 50 c/mL (ITT-snapshot) ; non-inferiority of DOR/3TC/TDF at W48 (and at W24) compared to continuation of cART at W24 if lower margin of a two-sided 95% CI for the adjusted difference = - 8% • Secondary : % of patients with HIV RNA ≥ 50 c/mL: non-inferiority of DOR/3TC/TDF at W48 (and at W24) compared to continuation of cART at W24, non-inferiority margin of 4% DRIVE-SHIFT Johnson M. J Acquir Immune DeficSyndr. 2019 Apr 11. [Epub ahead of print]

  3. DRIVE-SHIFT Study: Switch to DOR/3TC/TDF Baseline characteristics and patient disposition DRIVE-SHIFT Johnson M. J Acquir Immune DeficSyndr. 2019 Apr 11. [Epub ahead of print]

  4. DRIVE-SHIFT Study: Switch to DOR/3TC/TDF Primary endpoint: efficacy at 2 different time points, ITT Snapshot DOR/3TC/TDF immediate switch W48 Continuation cART W24 Immediate switch W24 Primary time point Secondary time point % 94.6 94.6 93.7 100 90.8 80 60 40 20 1.8 1.8 1.8 1.6 223 223 447 447 0 HIV RNA < 50 c/mL HIV RNA > 50 c/mL HIV RNA < 50 c/mL HIV RNA > 50 c/mL ≠ - 3.8% (IC 95 %: - 7.9 to 0.3) ≠ - 0.2% (- 2.5 to 2.1) ≠ - 0.9% (- 4.7 to 3.0) ≠ 0% (- 2.3 to 2.3) DRIVE-SHIFT Johnson M. J Acquir Immune DeficSyndr. 2019 Apr 11. [Epub ahead of print]

  5. DRIVE-SHIFT Study: Switch to DOR/3TC/TDF Drug resistance • Resistance analysis population, DOR/3TC/TDF immediate and deferred switch • Protocol-defined virologic failure, N = 7 • Discontinuation without protocol-defined virologic failure, N = 40 • No participant developed DOR or NRTI resistance • All 24 participants with baseline NNRTI mutations (K103N, Y181C, G190A) remained suppressed DRIVE-SHIFT Johnson M. J Acquir Immune DeficSyndr. 2019 Apr 11. [Epub ahead of print]

  6. DRIVE-SHIFT Study: Switch to DOR/3TC/TDF Adverse events, W24 * p < 0.0001 DRIVE-SHIFT Johnson M. J Acquir Immune DeficSyndr. 2019 Apr 11. [Epub ahead of print]

  7. DRIVE-SHIFT Study: Switch to DOR/3TC/TDF • Conclusion • Switching to DOR/3TC/TDF demonstrated non-inferior efficacy, at W24 and W48, compared to continuation of baseline cART through W24 • No emergence of resistance to DOR, 3TC or TDF • Favorable safety profile • Higher incidence of adverse events in participants who switched to DOR/3TC/TDF compared with those who continued their baseline regimen • Superior lipid profile for LDL-cholesterol and non-HDL cholesterol of DOR/3TC/TDF compared to continuation of a boosted-PI regimen DRIVE-SHIFT Johnson M. J Acquir Immune DeficSyndr. 2019 Apr 11. [Epub ahead of print]

More Related